157 related articles for article (PubMed ID: 30448190)
1. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.
Bai A; Bielawska A; Rahmaniyan M; Kraveka JM; Bielawski J; Hannun YA
Bioorg Med Chem; 2018 Dec; 26(23-24):6067-6075. PubMed ID: 30448190
[TBL] [Abstract][Full Text] [Related]
2. Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.
Bai A; Szulc ZM; Bielawski J; Pierce JS; Rembiesa B; Terzieva S; Mao C; Xu R; Wu B; Clarke CJ; Newcomb B; Liu X; Norris J; Hannun YA; Bielawska A
Bioorg Med Chem; 2014 Dec; 22(24):6933-44. PubMed ID: 25456083
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into ceramidase inhibitor LCL521-enhanced tumor cell killing by photodynamic and thermal ablation therapies.
Korbelik M; Zhao J; Zeng H; Bielawska A; Szulc ZM
Photochem Photobiol Sci; 2020 Sep; 19(9):1145-1151. PubMed ID: 32821888
[TBL] [Abstract][Full Text] [Related]
4. Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase.
Bai A; Mao C; Jenkins RW; Szulc ZM; Bielawska A; Hannun YA
PLoS One; 2017; 12(6):e0177805. PubMed ID: 28614356
[TBL] [Abstract][Full Text] [Related]
5. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.
Liu F; Li X; Lu C; Bai A; Bielawski J; Bielawska A; Marshall B; Schoenlein PV; Lebedyeva IO; Liu K
Oncotarget; 2016 Dec; 7(51):83907-83925. PubMed ID: 27880732
[TBL] [Abstract][Full Text] [Related]
6. Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.
Mizutani N; Inoue M; Omori Y; Ito H; Tamiya-Koizumi K; Takagi A; Kojima T; Nakamura M; Iwaki S; Nakatochi M; Suzuki M; Nozawa Y; Murate T
J Biochem; 2015 Oct; 158(4):309-19. PubMed ID: 25888580
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of erythro- B13 enantiomers and stereospecific action of full set of B13-isomers in MCF7 breast carcinoma cells: Cellular metabolism and effects on sphingolipids.
Bai A; Bielawski J; Bielawska A; Hannun YA
Bioorg Med Chem; 2021 Feb; 32():116011. PubMed ID: 33461145
[TBL] [Abstract][Full Text] [Related]
8. Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine.
Korbelik M; Banáth J; Zhang W; Saw KM; Szulc ZM; Bielawska A; Separovic D
Int J Cancer; 2016 Sep; 139(6):1372-8. PubMed ID: 27136745
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy.
Govindarajah N; Clifford R; Bowden D; Sutton PA; Parsons JL; Vimalachandran D
Crit Rev Oncol Hematol; 2019 Jun; 138():104-111. PubMed ID: 31092365
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and bioevaluation of omega-N-amino analogs of B13.
Bai A; Szulc ZM; Bielawski J; Mayroo N; Liu X; Norris J; Hannun YA; Bielawska A
Bioorg Med Chem; 2009 Mar; 17(5):1840-8. PubMed ID: 19217788
[TBL] [Abstract][Full Text] [Related]
11. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
13. Acid Ceramidase: A Novel Therapeutic Target in Cancer.
Vijayan Y; Lankadasari MB; Harikumar KB
Curr Top Med Chem; 2019; 19(17):1512-1520. PubMed ID: 30827244
[TBL] [Abstract][Full Text] [Related]
14. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.
Bedia C; Camacho L; Abad JL; Fabriàs G; Levade T
J Lipid Res; 2010 Dec; 51(12):3542-7. PubMed ID: 20871013
[TBL] [Abstract][Full Text] [Related]
15. Systemic ceramide accumulation leads to severe and varied pathological consequences.
Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
[TBL] [Abstract][Full Text] [Related]
16. Ceramidases, roles in sphingolipid metabolism and in health and disease.
Coant N; Sakamoto W; Mao C; Hannun YA
Adv Biol Regul; 2017 Jan; 63():122-131. PubMed ID: 27771292
[TBL] [Abstract][Full Text] [Related]
17. Atom based 3D-QSAR studies on 2,4-dioxopyrimidine-1-carboxamide analogs: Validation of experimental inhibitory potencies towards acid ceramidase.
Bhattacherjee D; Bhabak KP
Eur J Pharm Sci; 2016 Feb; 83():8-18. PubMed ID: 26658266
[TBL] [Abstract][Full Text] [Related]
18. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
19. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
[TBL] [Abstract][Full Text] [Related]
20. Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis.
Cho SM; Kwon HJ
Arch Pharm Res; 2019 Mar; 42(3):232-243. PubMed ID: 30661200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
